Drugs / IVB103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06737354 | Apr 2025 → Dec 2027 expected | wet macular degeneration | InnoVec Biotherapeutics Inc. | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVB103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06737354 ↗ |
| Route | Intravitreal | “Single intravitreal injection” NCT06737354 ↗ |